share_log

Recursion Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Gibson Christopher

Recursion Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Gibson Christopher

Recursion Pharmaceuticals | 4/A:持股變動聲明(修正)-高管 Gibson Christopher
美股sec公告 ·  07/12 18:58
Moomoo AI 已提取核心訊息
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, completed an acquisition of 100,000 shares of the company's Class A Common Stock on June 5, 2024. The transaction was carried out directly with no cost associated with the acquisition. Following this transaction, Gibson's total direct holdings in Recursion Pharmaceuticals amount to 908,738 shares. The transaction reflects a significant increase in the CEO's stake in the company, which could be indicative of his confidence in the firm's prospects.
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, completed an acquisition of 100,000 shares of the company's Class A Common Stock on June 5, 2024. The transaction was carried out directly with no cost associated with the acquisition. Following this transaction, Gibson's total direct holdings in Recursion Pharmaceuticals amount to 908,738 shares. The transaction reflects a significant increase in the CEO's stake in the company, which could be indicative of his confidence in the firm's prospects.
Recursion藥品的首席執行官Christopher Gibson在2024年6月5日以無成本直接獲得方式收購了該公司100,000股A類普通股,此次交易使Gibson在Recursion藥品的直接持股總數達到908,738股。這次交易反映出該公司的首席執行官對公司前景的信懇智能。
Recursion藥品的首席執行官Christopher Gibson在2024年6月5日以無成本直接獲得方式收購了該公司100,000股A類普通股,此次交易使Gibson在Recursion藥品的直接持股總數達到908,738股。這次交易反映出該公司的首席執行官對公司前景的信懇智能。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息